CKPT Checkpoint Therapeutics Inc.: Earnings per share for the trailing year

The relative YoY EPS growth over the last 12 months demonstrates profit dynamics, where the level of 49.50 is the current value. Checkpoint Therapeutics (CKPT) is implementing AI and robotics to accelerate the discovery of immuno-oncology agents. The company is creating affordable next-generation antibodies, gaining the trust of physicians. The anticipation of FDA approval for Cosibelimab serves as the primary driver, while previous liquidity risks are already priced in.

Checkpoint Therapeutics is a biotechnology startup focused on bringing an oncology drug to market by seeking a strategic partner. Annual EPS growth based on financial statements (TTM) measures the percentage change in net income per share over a rolling year, revealing systemic business degradation or development. This trend on the chart reflects the actual efficiency of capital management. For a company without active sales, such a metric serves as an indicator of the cash burn rate. Stability or growth in this value would confirm the fundamental resilience of the model prior to product commercialization.